Vor Bio secures global rights to RemeGen autoimmune drug with $175M funding

Published 26/06/2025, 07:12
Vor Bio secures global rights to RemeGen autoimmune drug with $175M funding

CAMBRIDGE, Mass. - Vor Bio (NASDAQ:VOR) has entered into an exclusive license agreement with RemeGen Co., Ltd. (HKEX:9995, SHA:688331) for global rights to telitacicept, a dual-target fusion protein approved in China for multiple autoimmune conditions, according to a press release statement.

The agreement grants Vor Bio rights to develop and commercialize telitacicept outside China, Hong Kong, Macau and Taiwan. Under the terms, Vor Bio will pay RemeGen an initial $125 million, consisting of a $45 million upfront payment plus $80 million in warrants. The deal includes potential regulatory and commercial milestones exceeding $4 billion, plus tiered royalties.

Telitacicept is currently in global Phase 3 development for generalized myasthenia gravis, with initial results expected in the first half of 2027. The drug is already approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis.

Separately, Vor Bio announced a $175 million private placement financing through the issuance of prefunded warrants to purchase 700 million shares at $0.25 per warrant. The PIPE financing is expected to close on June 27, 2025, subject to customary closing conditions.

The company also appointed Jean-Paul Kress, M.D., as Chief Executive Officer and Chairman of the Board, replacing Robert Ang, who will remain as a strategic advisor through October 2025.

PureTech Health plc (NASDAQ:PRTC, LSE:PRTC), which founded Vor Bio, currently holds approximately 2.1% ownership in the company as of May 8, 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.